BEIGF:OTCMKTS
BeOne Medicines
21,95 US$
0,00%
(0,00) 1D
9 ივნ, 12:49:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
42,40 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 US$
52-wk low
21,95 US$
Beta
0,84
Shares outstanding
1,43 მლრდ.
No. of employees
12 ათ.
Mkt. cap
42,40 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 US$
52-wk low
21,95 US$
Beta
0,84
Shares outstanding
1,43 მლრდ.
No. of employees
12 ათ.
News stories
From web sources and news partners
Sahi
·
17 წუთის წინ
Black Box Shows Interest In Nasdaq Listed Aeries Technology Reporting $70 Million FY26 Revenue
Yahoo Finance
·
1 საათის წინ
Why Are Nasdaq Futures Rising Premarket? MU, IREN, SLS, NIO, ASTS, WFF Stocks In Focus
The Mighty 790 KFGO
·
8 წუთის წინ
Wall Street’s big but narrow rally: 4 in 10 S&P stocks are down this year
Bloomberg.com
·
11 საათის წინ
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOჯონ ვინსენტ ოილერი | ჯონ ვინსენტ ოილერი
Employees12 ათ.
Founded28 ოქტ. 2010
Headquarters-
Sector-
Websitebeonemedicines.com